We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued final guidance for outsourcing facilities on compounding and repackaging radiopharmaceuticals, along with draft guidance on insanitary conditions at compounding facilities. Read More
The FDA released a trio of guidances on Drug Supply Chain and Security Act (DSCSA) requirements for drugmakers to attach identifiers to their prescription drugs. Read More
FDA guidance on submitting field alert reports contradicts federal regulations on the time frame for when reports must be submitted, Perrigo and GlaxoSmithKline said in public comments. Read More
The FDA added immediate-release opioids to its risk evaluation and mitigation strategy (REMS) for opioid analgesics, saying the move will encourage “rational prescribing.” Read More
The FDA issued guidance on how sponsors of synthetic drugs should approach post-approval manufacturing process changes — listing examples of low, medium and high risk changes. Read More
The tax puts generic drug manufacturers in the crosshairs, according to the group, because generics account for 90 percent of the volume of prescriptions dispensed but only 23 percent of spending. Read More
The draft puts day zero at the day the contract laboratory learns there’s a problem; existing regulations put day zero at the day the NDA or ANDA applicant learns there’s a problem. Read More
The CBO score validates what AAM and our member companies have been saying for years: that CREATES will reduce drug prices and increase access to medicines for patients who need it most,” said Rachel Schwartz, a spokesperson for the Association for Accessible Medicines. Read More